Fadeucravacitinib vs Nomelcitinib (D-2570)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Psoriasis

Shared mechanism: TYK2 · full Psoriasis pipeline

Fadeucravacitinib

Developed by Beijing InnoCare Pharma Tech Co.

Phase 3 in Psoriasissmall molecule
Partial signal

NCT06109818 · Phase 2 · completed

The trial randomized 129 participants to two ICP-488 dose groups or placebo and used quadruple blinding of participants, care providers, investigators, and outcome assessors. Its primary endpoint was the clinical psoriasis measure PASI 75 at Week 12, but the registry does not report whether the comparison was met.

Figures via dermatology news coverage of the sponsor's announcement; no peer-reviewed publication or registry results yet. Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Reported efficacy

Percentage of subjects who achieved a PASI 75 response (a reduction of minimum 75% from baseline in PASI score) at Week 12. (Baseline up to Week 12): PASI 75 at week 12: 77.3% (6 mg) and 78.6% (9 mg) vs 11.6% (placebo); primary endpoint achieved (met)

Result source: NCT06109818

Nomelcitinib (D-2570)

Developed by InventisBio

Phase 3 in PsoriasisSmall molecule (oral TYK2 JH2 pseudokinase-domain inhibitor)
Partial signal

NCT06278350 · Phase 2 · completed

The study randomized 161 participants with moderate to severe plaque psoriasis to three D-2570 dose groups or placebo, with participants, care providers and investigators masked. The primary endpoint, PASI 75 at week 12, was met in all three dose groups versus placebo (at least 85% vs 12.5%, p<0.001), per the sponsor's release and the peer-reviewed publication. The trial is mid-sized and 12 weeks long, so durability and safety beyond week 12 are not established.

Next expected readout: July 2027 · NCT07326813 (registry estimate)

Reported efficacy

Percentage of subjects with at least 75% improvement in PASI (Day 1-Day 85): Primary endpoint PASI 75 at week 12: ≥85% in all three D-2570 dose groups vs 12.5% with placebo (p<0.001) (met)

Result source: NCT06278350

Results for Psoriasis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointFadeucravacitinibNomelcitinib (D-2570)
PASI 75—Trial running · NCT06842199—Trial running · NCT07130604
PASI 90—Trial running · NCT06842199—Trial running · NCT07130604
PASI 100—Trial running · NCT06842199—Trial running · NCT07130604
sPGA 0/1—Trial running · NCT06842199—Trial running · NCT07130604
DLQI, change—Trial running · NCT06842199—Trial running · NCT07130604

PASI 75

Fadeucravacitinib
—Trial running · NCT06842199
Nomelcitinib (D-2570)
—Trial running · NCT07130604

PASI 90

Fadeucravacitinib
—Trial running · NCT06842199
Nomelcitinib (D-2570)
—Trial running · NCT07130604

PASI 100

Fadeucravacitinib
—Trial running · NCT06842199
Nomelcitinib (D-2570)
—Trial running · NCT07130604

sPGA 0/1

Fadeucravacitinib
—Trial running · NCT06842199
Nomelcitinib (D-2570)
—Trial running · NCT07130604

DLQI, change

Fadeucravacitinib
—Trial running · NCT06842199
Nomelcitinib (D-2570)
—Trial running · NCT07130604
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Fadeucravacitinib
PASI 75 at week 12: 77.3% (6 mg) and 78.6% (9 mg) vs 11.6% (placebo); primary endpoint achieved NCT06109818 · Phase 2 · design grade: moderate · publication or press release
Nomelcitinib (D-2570)
Primary endpoint PASI 75 at week 12: ≥85% in all three D-2570 dose groups vs 12.5% with placebo (p<0.001) NCT06278350 · Phase 2 · design grade: moderate · publication or press release

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Fadeucravacitinib's landscape · Nomelcitinib (D-2570)'s landscape